Astellas PharmaALPMF -11.99%72 5-Year Yield-on-Cost % is 7.23 as of Jul. 08, 2026, which is 54% above its 10-year median of 4.69. GuruFocus rates ALPMF with a GF Score™ of 72/100 and a GF Value™ of $14.19 (Fairly Valued). The stock has 4 warning signs investors should review. Among 517 Drug Manufacturers companies, Astellas Pharma ranks better than 82.4% on this metric.
Astellas Pharma's yield on cost for the quarter that ended in Mar. 2026 was 7.23.
The historical rank and industry rank for Astellas Pharma's 5-Year Yield-on-Cost % or its related term are showing as below:
ALPMF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.43 Med: 4.69 Max: 10.98
Current: 7.23
During the past 13 years, Astellas Pharma's highest Yield on Cost was 10.98. The lowest was 3.43. And the median was 4.69.
ALPMF's 5-Year Yield-on-Cost % is ranked better than 82.4% of 517
companies
in the Drug Manufacturers industry
Industry Median: 2.27
vs ALPMF: 7.23
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Astellas Pharma 5-Year Yield-on-Cost % Related Terms
ALPMF vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Astellas Pharma is calculated as
Astellas Pharma (ALPMF) has a 5-Year Yield-on-Cost % of 7.23 as of Jul. 08, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Astellas Pharma and its competitors. This is 54% above median its historical median of 4.69. Over the past decade, Astellas Pharma's 5-Year Yield-on-Cost % has ranged from 3.43 to 10.98. According to the industry distribution chart, Astellas Pharma ranks #91 out of 517 companies in the Drug Manufacturers industry, placing it in the top 17.6%.
Is Astellas Pharma's 5-Year Yield-on-Cost % too high?
Astellas Pharma's current 5-Year Yield-on-Cost % of 7.23 is 54% above median its 10-year median of 4.69. Over the past 10 years, this metric has ranged from a low of 3.43 to a high of 10.98. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.27. Astellas Pharma's value of 7.23 is 218.5% above this industry median. Based on the distribution chart, Astellas Pharma ranks #91 out of 517 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Astellas Pharma has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #91 out of 517 companies for 5-Year Yield-on-Cost %. This places Astellas Pharma in the top 18% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.27. Astellas Pharma's value of 7.23 is 218.5% above this benchmark. Historically, Astellas Pharma's own 5-Year Yield-on-Cost % has ranged from 3.43 to 10.98 over the past decade. While the company's 10-year median is 4.69 vs. the industry median of 2.27, Astellas Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.27, based on 517 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current 5-Year Yield-on-Cost % of 7.23 is 218.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current 5-Year Yield-on-Cost % is 7.23, which is 54% above median its own 10-year median of 4.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.19, compared to a current price of $12.85 — trading 9.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 7.23, which is 54% above median its 10-year median of 4.69 and 218.5% above the Drug Manufacturers industry median of 2.27. Astellas Pharma's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current 5-Year Yield-on-Cost % is 7.23 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $12.85 is trading 9.4% below its estimated GF Value™ of $14.19.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
5-Year Yield-on-Cost %: 7.23 (54% above median its 10-year median of 4.69)
GF Value™: $14.19 vs. price of $12.85 (9.4% below fair value)
Industry Position: 218.5% above the Drug Manufacturers median (#91 of 517)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
72GF Score
Get the complete analysis for ALPMF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 